GH Solutions

GH Solutions, based in the US, focuses on distributing diagnostic testing products, particularly drug of abuse tests. Their emphasis on quality and reliability supports various workplace and healthcare testing scenarios. GH Solutions is dedicated to the distribution of drug testing diagnostics, providing services primarily in the US. The company has not changed its core business strategy significantly since its inception.

Currently headquartered in the United States, GH Solutions has engaged in 1 deal, with the most recent occurring on April 9, 2026. The company was acquired by PREMIER BIOTECH, LLC, a portfolio of Align Capital Partners, which is expected to enhance its growth trajectory. GH Solutions specializes in a comprehensive range of drug of abuse testing products, emphasizing quality and reliability. Their core offerings include FDA Cleared point-of-care diagnostics utilizing lateral flow immunoassay technology for saliva and urine tests.

These products are designed for various workplace testing scenarios, such as pre-employment, post-accident, and random testing. The company services a diverse clientele including clinical facilities, physicians, and drug treatment centers, and markets its products across North America and Europe, enhancing access to reliable drug testing solutions. GH Solutions generates revenue through direct sales of its diagnostic testing products to healthcare providers and corporate clients. These B2B transactions typically involve bulk purchases or specific testing configurations for up to 14 different drugs.

While specific pricing details are not disclosed, the company is known for providing flexible options to meet diverse testing needs. By focusing on CLIA Waived products that are CE marked and 510k FDA cleared, GH Solutions secures a steady revenue stream from its established client base. Following its acquisition by PREMIER BIOTECH, LLC on April 9, 2026, GH Solutions is positioned to accelerate its growth. The acquisition is intended to support the development of new products and expand into new geographical markets.

Specific plans for product launches and geographic expansions have not been detailed but align with the strategic goals of PREMIER BIOTECH to enhance their portfolio.